ZVSA – zyversa therapeutics, inc. (US:NASDAQ)
Stock Stats
News
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Form 10-Q ZyVersa Therapeutics, For: Mar 31
Form 10-K/A ZyVersa Therapeutics, For: Dec 31
Form 8-K ZyVersa Therapeutics, For: Apr 17
Form DEFA14A ZyVersa Therapeutics,
Form 10-K ZyVersa Therapeutics, For: Dec 31
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.